Iterum Therapeutics Plc Stock Market Value
| ITRM Stock | USD 0.36 0.01 2.86% |
| Symbol | Iterum |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.72) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Iterum Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Iterum Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Iterum Therapeutics.
| 10/27/2025 |
| 01/25/2026 |
If you would invest 0.00 in Iterum Therapeutics on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Iterum Therapeutics PLC or generate 0.0% return on investment in Iterum Therapeutics over 90 days. Iterum Therapeutics is related to or competes with Intensity Therapeutics, IBio Common, Rallybio Corp, Pluri, AN2 Therapeutics, Boundless Bio, and TAO Synergies. Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infecti... More
Iterum Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Iterum Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Iterum Therapeutics PLC upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 28.58 | |||
| Value At Risk | (8.82) | |||
| Potential Upside | 9.38 |
Iterum Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Iterum Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Iterum Therapeutics' standard deviation. In reality, there are many statistical measures that can use Iterum Therapeutics historical prices to predict the future Iterum Therapeutics' volatility.| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (1.08) | |||
| Total Risk Alpha | (1.49) | |||
| Treynor Ratio | (0.43) |
Iterum Therapeutics January 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (0.42) | |||
| Mean Deviation | 4.36 | |||
| Coefficient Of Variation | (656.26) | |||
| Standard Deviation | 6.04 | |||
| Variance | 36.49 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.08) | |||
| Total Risk Alpha | (1.49) | |||
| Treynor Ratio | (0.43) | |||
| Maximum Drawdown | 28.58 | |||
| Value At Risk | (8.82) | |||
| Potential Upside | 9.38 | |||
| Skewness | (0.30) | |||
| Kurtosis | 3.15 |
Iterum Therapeutics PLC Backtested Returns
Iterum Therapeutics PLC holds Efficiency (Sharpe) Ratio of -0.13, which attests that the entity had a -0.13 % return per unit of risk over the last 3 months. Iterum Therapeutics PLC exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Iterum Therapeutics' Market Risk Adjusted Performance of (0.42), risk adjusted performance of (0.10), and Standard Deviation of 6.04 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 2.18, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Iterum Therapeutics will likely underperform. At this point, Iterum Therapeutics PLC has a negative expected return of -0.82%. Please make sure to check out Iterum Therapeutics' treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Iterum Therapeutics PLC performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.44 |
Average predictability
Iterum Therapeutics PLC has average predictability. Overlapping area represents the amount of predictability between Iterum Therapeutics time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Iterum Therapeutics PLC price movement. The serial correlation of 0.44 indicates that just about 44.0% of current Iterum Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.44 | |
| Spearman Rank Test | 0.53 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Iterum Therapeutics Correlation, Iterum Therapeutics Volatility and Iterum Therapeutics Alpha and Beta module to complement your research on Iterum Therapeutics. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Iterum Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.